Licensing Services

Providing scientific innovation a boost towards clinical development and commercial milestone achievement
Request for proposal
Moving from a scientific to a business-oriented outlook is an inherent challenge of the Pharma market. Which is why, many blockbuster drugs of Big Pharma Players have been licensed in from small Pharma players or academia centres of research universities, as the former entities have a great sense of business. Correctly called other’s science, these drugs receive a platform to perform exceptionally well in the market. Still, such licensing processes possess inherent challenges.

Our Perspective

Here comes in our game-modifying role, where we assist either of the entities to find the other through our proprietary licensing service offering. Designed in such a way that we find- every time- the best strategic licensing partner for our clients. Having speciality of all therapeutic areas and networks across the globe, we are expertly positioned to provide the best consulting advice.
Our Licensing Services provides you:

Insights

In-licensing opportunity study

In-Licensing Opportunity

A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe [...]

Out-licensing opportunity study

Out-Licensing Opportunity

A Small Pharmaceutical Client Based At Sweden, Europe With Capabilities Around A Neonatal Mesenchymal Cells Involved DelveInsight [...]

Assest prioritization study

Asset Prioritization

A mid-sized pharma client was working to develop their asset portfolio, and was interested to assess best possible asset for atrial fibrillation [...]

Regulatory Analysis study

Regulatory Analysis

A large client based in Europe, involved in Dermatology arena with a market-ready product, aimed to assess the Indian Regulatory Scenario to successfully file the product in CDSCO. [...]

Request For Proposal

*I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.